Literature DB >> 8093682

An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia.

L M Gunne1, P E Andrén.   

Abstract

There is now ample evidence for long-term malfunctioning within five different brain GABAergic pathways in a monkey model for tardive dyskinesia (TD). Three of these GABA connections (GPe-STN, CP-SNr, and CP-GPi) are chronically downregulated during neuroleptic treatment and after some years they do not seem to regain their normal activity, even when the neuroleptics are discontinued. The persistent downregulation of these three GABA connections, evidenced by depressions of terminal GAD activity and GABA levels, appears to be a conceivable mechanism behind tardive parkinsonism (TP), often reported to coexist with TD in the clinic. The TD patients' well-known lack of awareness of their symptoms may be due to their parkinsonian "sensory neglect." Another two GABA malfunctioning connections were found in our monkey model: SNr-VA/VL and GPi-VA/VL. These pathways are upregulated during chronic neuroleptic treatment, partly due to an elevated glutamate release within subthalamofugal pathways. This chronic glutamatergic hyperactivity may have acted via an excitotoxic mechanism and consequently both GPi and VA/VL had a low synaptic activity in our dyskinetic monkeys, as measured by 2-deoxyglucose uptake, even 4 months after the last neuroleptic dose. It is hypothesized that TD may be due to an excitotoxic lesion of the inhibitory GABAergic VA/VL afferents, while TP has to do with persistent malfunctioning of downregulated SNr and GPi afferents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093682     DOI: 10.1097/00002826-199302000-00012

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  7 in total

Review 1.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 2.  [Antipsychotic-induced tardive syndromes].

Authors:  W Wolfgang Fleischhacker; Alex Hofer; Christian Jagsch; Walter Pirker; Georg Psota; Hans Rittmannsberger; Klaus Seppi
Journal:  Neuropsychiatr       Date:  2016-08-31

Review 3.  An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda.

Authors:  Narendra Singh; Mohit Bhalla; Prashanti de Jager; Marilena Gilca
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-07-03

4.  Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.

Authors:  C K Meshul; O A Andreassen; C Allen; H A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

5.  Drug-induced parkinsonism.

Authors:  Hae-Won Shin; Sun Ju Chung
Journal:  J Clin Neurol       Date:  2012-03-31       Impact factor: 3.077

Review 6.  Relevance of animal models to human tardive dyskinesia.

Authors:  Pierre J Blanchet; Marie-Thérèse Parent; Pierre H Rompré; Daniel Lévesque
Journal:  Behav Brain Funct       Date:  2012-03-09       Impact factor: 3.759

Review 7.  Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism.

Authors:  Elena E Vaiman; Natalia A Shnayder; Aiperi K Khasanova; Anna I Strelnik; Arseny J Gayduk; Mustafa Al-Zamil; Margarita R Sapronova; Natalia G Zhukova; Daria A Smirnova; Regina F Nasyrova
Journal:  Biomedicines       Date:  2022-08-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.